In clinical work, it was found that the majority of hepatitis B patients who took entecavir and tenofovir took the medicine, and most of them did not re-examine after taking the medicine, and they did not know whether the condition recovered or worsened.
【3 Benefits:】
Benefit (1): Hepatitis B virus will be lower than the lower limit of detection, as a first-line antiviral drug, the efficacy of these two drugs is still very good, generally speaking, regular use of antiviral drugs, within 12 months of viral DNA will be negative, and the infectivity will be significantly reduced.
Benefit (2): Liver function and ultrasound will improve, after viral replication is inhibited, liver function aminotransferases can remain stable for a long time, hepatitis activity is inhibited, and echo enhancement and thickening of liver ultrasound suggestive of liver fibrosis will generally improve.
Benefit (3): The big three yangs may become the small three yangs. Some patients can have the situation of turning from big three yang to small three yang, and the condition is gradually stabilized. Yesterday, a local hepatitis B patient in Jinan came for reexamination, the surface antigen has turned negative, and the antibody titer is not high, so it is recommended that he be vaccinated with hepatitis B vaccine for 3 consecutive months to stimulate the appearance of antibodies.
[2 disadvantages:]
Viral resistance and hypoviremia. In some patients, the virus may turn negative and then rise again, which may be due to drug resistance. Of course, the resistance rate of these two drugs is much lower than that of the eliminated lamivudine, telbivudine and adefovir disody, and some hepatitis B patients have the virus dropped to less than 2000 after 2 years of antiviral treatment, and it is found to be greater than 20 by high-sensitivity detection, which is a fashionable term in recent years: hypoviremia.
If viral resistance and hypoviremia occur during the antiviral period of hepatitis B, the treatment regimen needs to be adjusted promptly.